Open Access Highly Accessed Research article

Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials

Clive Elliott Adams1*, John Rathbone1, Ben Thornley1, Mike Clarke2, Jo Borrill3, Kristian Wahlbeck4 and A George Awad5

Author Affiliations

1 Cochrane Schizophrenia Group, Academic Department of Psychiatry and Behavioural Sciences, University of Leeds, 15 Hyde Terrace, Leeds, LS2 9LT, UK

2 UK Cochrane Centre, Summertown Pavilion, Middle Way, Summertown, Oxford, OX2 7LG, UK

3 Safer Custody Group, HM Prison Service, Abell House, John Islip Street, London, SW1P 4LH, UK

4 STAKES/Vasa Central Hospital, Department of Psychiatry, FIN-65130 Vaasa, Finland

5 University of Toronto, Humber River Regional Hospital, Keele Street Site, 2175 Keele Street, Toronto, Ontario, M6M 3Z4, Canada

For all author emails, please log on.

BMC Medicine 2005, 3:15  doi:10.1186/1741-7015-3-15

Published: 17 October 2005

Additional files

Additional File 1:

Search strategy for identification of studies. The Schizophrenia Group's register is based on regular searches of BIOSIS Inside; CENTRAL; CINAHL; EMBASE; MEDLINE and PsycINFO; the hand searching of relevant journals and conference proceedings, and searches of several key grey literature sources. A full description is given in the Group's module on the Cochrane Library.

Format: DOC Size: 54KB Download file

This file can be viewed with: Microsoft Word Viewer

Open Data